(TheNewswire)
Winnipeg – TheNewswire - February 12, 2024 - Cytophage Technologies Ltd. (TSXV:CYTO)(“Cytophage” or the “Company”) is pleased to announced that ithas completed research and development of its OvaPhage product, and ispreparing to conduct field trials in Canada as a final step beforecommercialization. Cytophage has been in longstanding discussionswith Canadian industry leaders who have sought alternatives to thecurrently available disinfectant products used in egg production. Asa result, Cytophage has developed OvaPhage, its next product in the FarmPhage line. OvaPhage is abacteriophage product that will address b acteriasuch as Salmonella,Escherichia, and Shigella on thesurface of eggs. OvaPhage is adisinfectant bacteriophage product that, in laboratory studies,reduces 90% of bacterial load on egg shells . OvaPhage is also environmentally friendly, non-toxic anddoes not damage the cuticle of the egg.
Cytophage developed OvaPhage based on its proprietarybacteriophage technology, and has tested it in its laboratories overthe past 9 months. Cytophage is now preparing for fieldtrials which will involve testing the product in poultry barns. OvaPhage will be sprayed on the eggs using the existing closed spraysystems available in poultry barns. The Company’s national poultry advisor has indicated that Canadian eggproducers would welcome new products that will decrease spoilage andincrease revenues while not requiring new application processes.
To facilitate this step, an Experimental Studies Certificateapplication is being prepared for submission to the Canadian FoodInspection Agency. An application for regulatory approval in theUnited States has been submitted and a similar regulatory approvalsubmission for Canada is currently being developed. Upon completion of field testing and regulatory approvals,the Company expects to commence commercialization of OvaPhage acrossCanada.
“OvaPhage is one of severalproduct developments that Cytophage aims to commercialize in 2024 withour proprietary bacteriophagetechnology,” said Dr Steven Theriault, CEOof Cytophage. “ Canada is a global leader in maximizing eggproduction. We believe that the successful field testing andcommercialization of OvaPhage in Canada will strongly position theproduct for distribution across the globe. Welook forward to providing continued updates as to additionalbacteriophage products and applications in both animal health andhuman health"
For media inquiries:
Heather Medwick
President
heather@cytophage.com
431 388 8873
About Cytophage:
Cytophage is a pioneering biotechnology company dedicated tobacteriophage research, product development and commercialization.Committed to addressing the global challenge of antibiotic resistance,Cytophage advances innovative products that harness the power ofbacteriophages to combat bacterial infections affecting human health,animal health, and food security.
Cautionary Statement on Forward-Looking Information
This news release contains “forward-looking information” and“forward-looking statements” (collectively, “forward-lookingstatements”) within the meaning of the applicable Canadiansecurities legislation. All statements, other than statements ofhistorical fact, are forward-looking statements and are based onexpectations, estimates and projections as at the date of this newsrelease. Any statement that involves discussions with respect topredictions, expectations, beliefs, plans, projections, objectives,assumptions, future events or performance (often but not always usingphrases such as “expects”, or “does not expect”, “isexpected”, “anticipates” or “does not anticipate”,“plans”, “budget”, “scheduled”, “forecasts”,“estimates”, “believes” or “intends” or variations of suchwords and phrases or stating that certain actions, events or results“may” or “could”, “would”, “might” or “will” betaken to occur or be achieved) are not statements of historical factand may be forward-looking statements. Forward-looking statementsinvolve known and unknown risks, uncertainties and other factors whichmay cause the actual results, performance or achievements of Cytophageto be materially different from any future results, performance orachievements expressed or implied by the forward-looking statements.Factors that could cause actual results to differ materially fromthose anticipated in these forward-looking statements are describedunder the caption “Risk Factors” in Cytophage’s Filing Statementdated January 30, 2024, which is available for view on SEDAR+ atwww.sedarplus.ca. These risks include but are not limited to, therisks associated with the bacteriophage industry, such as operationalrisks in development or capital expenditures, the uncertainty ofextensive regulatory approval requirements, government regulations,protection of intellectual property, product liability and rapidtechnological advancements. Forward-looking statements containedherein are made as of the date of this press release, and Cytophagedisclaims, other than as required by law, any obligation to update anyforward-looking statements whether as a result of new information,results, future events, circumstances, or if management’s estimatesor opinions should change, or otherwise. There can be no assurancethat forward-looking statements will prove to be accurate, as actualresults and future events could differ materially from thoseanticipated in such statements. Accordingly, the reader is cautionednot to place undue reliance on forward-looking statements. Neither theTSXV nor its Regulation Services Provider (as that term is defined inthe policies of the TSXV)
Copyright (c) 2024 TheNewswire - All rights reserved.